Lupin shares in focus as U.S. FDA approves its Pitolisant Tablets
Why did Lupin Ltd shares fall today?
Lupin Ltd shares saw a slight decline of , trading at around . This movement occurred despite the company announcing positive news from the United States. The minor dip could be due to overall market conditions or investors booking profits after recent gains, rather than a negative reaction to the announcement itself.
The news in question is that Lupin has received for its (in 4.45 mg and 17.8 mg strengths). This approval allows Lupin to market its generic version of the drug in the United States. The FDA has confirmed that Lupin's tablets are bioequivalent to the reference brand drug, , and can be used for the same approved medical indications.
In simple terms, this is a significant achievement for the company, granting it entry into the U.S. market for this specific medication. Such approvals typically expand a pharmaceutical company's product portfolio and revenue potential. However, on the day of the announcement, the positive development was not enough to drive the share price higher, leading to the marginal decline observed in the afternoon trading session.
What does Lupin Ltd do?
Lupin Limited is a global pharmaceutical major. It has received final approval from the U.S. FDA for the marketing and sale of Pitolisant Tablets.
The company is registered in Mumbai, India, and maintains a presence in both Mumbai and Naples. It is listed on major Indian stock exchanges under the symbol LUPIN and the equity code 500257.
Lupin Ltd Financials
In CroresBased on the provided data, Lupin Ltd's revenue increased from ₹7,391.91 crores in March 2026 to ₹8,217.23 crores in June 2026, indicating a quarter-on-quarter growth. However, the profit saw a slight decline, moving from ₹1,460.34 crores in March 2026 to ₹1,415.0 crores in June 2026.
Lupin Ltd Shareholding Pattern
Promoter holding stands at 46.85% of the total share capital. Foreign Institutional Investors (FIIs) hold 22.42% stake in the company, while Domestic Institutional Investors (DIIs) hold 24.65%. Public shareholders hold the remaining 6.08% stake in Lupin Ltd.
Lupin Ltd FAQs
Q: Why did Lupin shares fall 0.41% today?
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Lupin Ltd?
As per the latest data, promoters hold 46.85% stake in Lupin Ltd, while FII holding stands at 22.42%. Domestic institutional investors hold 24.65%, and public shareholders account for 6.08% of the equity.
Q: What is the current stock price of Lupin Ltd?
Lupin Ltd shares are currently trading at ₹2225.8, recording a decline of 0.41% from the previous close.
Q: What is the market capitalization of Lupin Ltd?
The company currently has a market capitalization of ₹101711.93 crore, reflecting its valuation in the Indian equity market.